CSPC Pharmaceutical Receives China Approvals for Three Clinical Trials
CSPC Pharmaceutical Group has received approval from China's National Medical Products Administration to begin clinical trials for three drug candidates: a hemophilia A biosimilar, a long-acting pain medication, and an injection designated SYH9089.
CSPC Pharmaceutical Group has received approval from China's National Medical Products Administration to begin clinical trials of its Emicizumab Injection (SYS6053), a biosimilar to Hemlibra for treating Hemophilia A. The modified bispecific humanized monoclonal antibody showed high similarity to the reference drug in quality, safety and efficacy in preclinical studies.
The company also received Chinese regulatory approval to begin clinical trials of its Ropivacaine Long-Acting Injection in China.
Additionally, CSPC Pharmaceutical Group received Chinese regulatory approval to begin clinical trials of its SYH9089 injection in China.
The approvals position CSPC to enter China's hemophilia biologics market and potentially broaden its hematology portfolio if clinical development succeeds. CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company focused on developing and manufacturing innovative and generic drugs, including biologics. The group targets major therapeutic areas in China and globally, leveraging its research capabilities to expand its portfolio of advanced treatments across key disease segments.